New MDR modulators such as tazemetostat [15], an I-CBP112-CBP/EP300 bromodomain inhibitor [16], or sonidegib [17] may increase the tumor cells’ sensitivity to anticancer agents by the functional inhibition of ABCG2. The gene discussed is ABCG2; the disease is neoplasm.